The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy.

The introduction of immune checkpoint inhibitors (ICIs), antibodies that target co-inhibitory molecules to improve anti-tumor immune responses, has dramatically changed the therapeutic landscape of several malignancies, particularly that of lung cancer (1,2).

[1]  T. Mok,et al.  Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. , 2018, Journal of Clinical Oncology.

[2]  N. Le Stang,et al.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. T. Jørgensen,et al.  Companion and Complementary Diagnostics–Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non–Small Cell Lung Cancer , 2017, Therapeutic drug monitoring.

[5]  D. Carbone,et al.  First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung Cancer , 2017 .

[6]  J. Taube,et al.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[7]  V. Prasad,et al.  Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. , 2017, Seminars in oncology.

[8]  J. Soria,et al.  Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? , 2017, BMC Medicine.

[9]  L. Essioux,et al.  Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch , 2017, Clinical and translational science.

[10]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Alan Sharpe,et al.  Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[12]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[13]  M. Tiemann,et al.  Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.

[14]  S. Gettinger,et al.  Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Rizvi,et al.  PD-L1 expression in advanced NSCLC: Primary lesions versus metastatic sites and impact of sample age. , 2016 .

[16]  K. Kerr,et al.  Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. , 2016, Archives of pathology & laboratory medicine.

[17]  F. Hirsch,et al.  Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? , 2016, Archives of pathology & laboratory medicine.

[18]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[19]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[20]  Ming-Sound Tsao,et al.  Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[22]  Christopher-Paul Milne,et al.  Complementary versus companion diagnostics: apples and oranges? , 2015, Biomarkers in medicine.

[23]  Vanessa M. Hubbard-Lucey,et al.  Comprehensive analysis of the clinical immuno-oncology landscape , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.